La d Which of the following clotting factors would have decreased gamma carboxyglutamate residue in patients on warfarin therapy?

Correct Answer: B. Factor 2

Warfarin is a vitamin K antagonist that inhibits the gamma-carboxylation of vitamin K-dependent clotting factors. This post-translational modification adds gamma-carboxyglutamate (Gla) residues to the N-terminal region of these factors, which are essential for calcium binding and phospholipid membrane interaction during coagulation. Factor II (prothrombin) is a vitamin K-dependent factor synthesized in the liver. Without adequate vitamin K (blocked by warfarin), the carboxylase enzyme cannot add Gla residues to prothrombin, resulting in undercarboxylated (PIVKA-II) or des-gamma-carboxyl prothrombin. This non-functional form cannot bind calcium and phospholipids effectively, leading to prolonged PT/INR. The other vitamin K-dependent factors (II, VII, IX, X) all suffer the same fate, but Factor II is the most clinically significant and the classic answer in Indian medical curricula. Warfarin's anticoagulant effect is primarily measured by PT, which reflects Factor II deficiency. In Indian clinical practice, warfarin monitoring via INR (which reflects Factor II and VII levels) is standard for VTE prophylaxis and AF management.

Why the other options are wrong

A. Factor 11 — Factor XI (not Factor 11 in standard nomenclature, though sometimes written as 11) is NOT vitamin K-dependent. It is a contact factor (part of the intrinsic pathway) synthesized in the liver but does not require gamma-carboxylation. Warfarin does not affect Factor XI levels or function. This is a distractor that tests knowledge of which factors are vitamin K-dependent versus those that are not. C. Tissue factor — Tissue factor (TF, Factor III) is a membrane-bound protein that is NOT vitamin K-dependent. It is constitutively expressed on extravascular cells and initiates the extrinsic pathway. Warfarin does not affect tissue factor synthesis or gamma-carboxylation. This is a common trap because TF is involved in coagulation, but it is not a substrate for the vitamin K-dependent carboxylase. D. Factor 5 — Factor V (not Factor 5 in standard nomenclature) is a non-vitamin K-dependent cofactor synthesized in the liver and megakaryocytes. Although Factor V levels may be slightly reduced in severe liver disease, warfarin does not directly impair its gamma-carboxylation because Factor V does not contain Gla residues. This is a trap for students who confuse 'liver synthesis' with 'vitamin K-dependence.'

High-Yield Facts

Mnemonics

Vitamin K-Dependent Factors (2-7-9-10) 2 (Prothrombin/Factor II), 7 (Proconvertin), 9 (Christmas), 10 (Stuart-Prower). All require gamma-carboxylation for function. Warfarin blocks all four. PIVKA Memory Hook PIVKA = Proteins Induced by Vitamin K Absence. These are undercarboxylated, non-functional forms that accumulate during warfarin therapy. PIVKA-II is used as a marker of warfarin effect in some labs.

NBE Trap

NBE pairs warfarin with 'liver synthesis' to lure students into selecting Factor V or XI (also liver-synthesized but not vitamin K-dependent). The key discriminator is gamma-carboxylation requirement, not just hepatic origin.

Clinical Pearl

In Indian practice, a patient on warfarin with INR >4 has deficient Factor II (and VII), explaining the prolonged PT. If you see a patient with bleeding on warfarin, remember it's the undercarboxylated, calcium-binding-deficient Factor II that cannot generate thrombin efficiently—fresh frozen plasma (FFP) or vitamin K reversal restores Gla residues.

_Reference: Guyton & Hall Textbook of Medical Physiology (Ch. 36: Hemostasis and Blood Coagulation); KD Tripathi Pharmacology (Ch. 16: Anticoagulants)_